QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)

Search documents
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
Globenewswire· 2025-05-27 12:00
Core Insights - Palvella Therapeutics has appointed Ashley Kline as Chief Commercial Officer to lead the commercial buildout for the planned standalone U.S. launch of QTORIN™ rapamycin anhydrous gel, targeting microcystic lymphatic malformations, a rare genetic disease affecting over 30,000 patients in the U.S. if approved [1][5] - Kline has a successful track record in the commercialization of therapies for rare diseases, having previously led the launch of Oxervate® at Dompé Pharmaceuticals, which achieved over $500 million in annual U.S. sales by 2023 [2][3] Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases without FDA-approved treatments [5] - The company is developing a pipeline of product candidates based on its patented QTORIN™ platform, with QTORIN 3.9% rapamycin anhydrous gel as its lead candidate currently in Phase 3 and Phase 2 clinical trials [5][6] Leadership and Strategy - Ashley Kline's leadership is expected to enhance Palvella's commercial organization, leveraging her experience in launching FDA-approved therapies for rare diseases [3][4] - Kline's approach emphasizes high-impact physician outreach and education, which contributed to the success of Oxervate® and is anticipated to be applied to Palvella's strategies [2][3]